Literature DB >> 3068036

Octreotide: a synthetic analog of somatostatin.

J M Rosenberg1.   

Abstract

Octreotide is an investigational synthetic peptide exhibiting actions similar to those of endogenous somatostatin. It has a longer half-life than the native hormone and can be administered by subcutaneous injection. Octreotide inhibits the secretion of growth hormone and numerous regulatory peptides of the gastroenteropancreatic system. Trials evaluating the clinical utility of octreotide indicate efficacy in the management of symptoms associated with acromegaly and hypersecretory neuroendocrine tumors, and in the control of nontumoral secretory diarrheas. Octreotide therapy is well tolerated. This agent should prove useful in the symptomatic control of a number of rare hypersecretory disorders.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3068036     DOI: 10.1177/106002808802201001

Source DB:  PubMed          Journal:  Drug Intell Clin Pharm        ISSN: 0012-6578


  5 in total

Review 1.  Peptide receptor radionuclide therapy using radiolabeled somatostatin analogs: focus on future developments.

Authors:  Sander M Bison; Mark W Konijnenberg; Marleen Melis; Stefan E Pool; Monique R Bernsen; Jaap J M Teunissen; Dik J Kwekkeboom; Marion de Jong
Journal:  Clin Transl Imaging       Date:  2014-03-05

2.  Improvement in the intestinal processes of hydroelectrolytic absorption and secretion in abdominal pathologies of surgical interest treated with SMS 201-995: experimental protocol.

Authors:  F F Guiró; G Bertolini; J V Salas
Journal:  Surg Today       Date:  1999       Impact factor: 2.549

Review 3.  A risk-benefit assessment of octreotide in the treatment of acromegaly.

Authors:  A J van der Lely; W W de Herder; S W Lamberts
Journal:  Drug Saf       Date:  1997-11       Impact factor: 5.606

4.  Effects of octreotide on circulating islet B cell products in endogenous hyperinsulinism.

Authors:  A J Krentz; J Pace; W Somerville; P M Clark; M Nattrass
Journal:  Postgrad Med J       Date:  1993-09       Impact factor: 2.401

Review 5.  Octreotide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in conditions associated with excessive peptide secretion.

Authors:  P E Battershill; S P Clissold
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.